The Helicobacter Eradication Aspirin Trial (HEAT): A Large Simple Randomised Controlled Trial Using Novel Methodology in Primary Care

Jennifer S. Dumbleton*, Anthony J. Avery, Carol Coupland, F. D.Richard Hobbs, Denise Kendrick, Michael V. Moore, Clive Morris, Greg P. Rubin, Murray D. Smith, Diane J. Stevenson, Chris J. Hawkey

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

19 Citations (SciVal)
16 Downloads (Pure)

Abstract

Background: Clinical trials measuring the effect of an intervention on clinical outcomes are more influential than those investigating surrogate measures but are costly. We developed methods to reduce costs substantially by using existing data in primary care systems, to ask whether Helicobacter pylori eradication would reduce the incidence of hospitalisation for ulcer bleeding in aspirin users. Methods: The Helicobacter Eradication Aspirin Trial (HEAT) is a National Institute of Health Research-funded, double-blind placebo controlled randomised trial of the effects of H. pylori eradication on subsequent ulcer bleeding in infected individuals taking aspirin daily, conducted in practices across the whole of England, Wales and Northern Ireland. A bespoke web-based trial management system developed for the trial (and housed within the secure NHS Data Network) communicates directly with the HEAT Toolkit software downloaded at participating practices, which issues queries searching entry criteria (≥ 60 years, on chronic aspirin ≤ 325 mg daily, not on anti-ulcer therapy or non-steroidal anti-inflammatory drugs) for GP review of eligibility. Trial participation is invited using a highly secure automated online mail management system. Interested patients are seen once for consent and breath testing. Those with a positive test are randomised to eradication treatment (lansoprazole, clarithromycin, metronidazole) or placebo, with drug sent by post. Events are tracked by upload of accumulating information in the GP database, patient contact, review of National Hospital Episode Statistics and Office of National Statistics data. Results: HEAT is the largest Clinical Research Network-supported drug trial, with 115,660 invitation letters sent from 850 practices, 22,922 volunteers, and 3038 H. pylori positive patients randomised to active or placebo treatment after 2.5. years of recruitment. 178 practices have performed their first follow-up data search to identify 21 potential endpoints to date. Discussion: HEAT is important medically, because aspirin is so widely used, and methodologically, as a successful trial would show that large-scale studies of important clinical outcomes can be conducted at a fraction of the cost of those conducted by industry, which in turn will help to ensure that trials of primarily medical rather than commercial interest can be conducted successfully in the UK.

Original languageEnglish
Pages (from-to)1200-1204
Number of pages5
JournalEBioMedicine
Volume2
Issue number9
DOIs
Publication statusPublished - 01 Sept 2015

Keywords

  • Aspirin
  • Bleed
  • Clinical trial
  • Helicobacter pylori
  • Ulcer
  • Disease Eradication
  • Humans
  • Treatment Outcome
  • Helicobacter/drug effects
  • Aspirin/adverse effects
  • Sample Size
  • Primary Health Care
  • Patient Compliance

Fingerprint

Dive into the research topics of 'The Helicobacter Eradication Aspirin Trial (HEAT): A Large Simple Randomised Controlled Trial Using Novel Methodology in Primary Care'. Together they form a unique fingerprint.

Cite this